Determining Criteria for Predicting Stenosis With Ultrasound Duplex After Endovascular Intervention in Infrainguinal Lesions

Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease

“…The duplex criterion used to determine the presence of in-stent Ն50% stenosis was an increase in the intrastenotic peak systolic velocity (PSV) of 140% in reference to the proximal prestenotic PSV from the same vessel segment (PSV ratio Ն2.4). 18,19 Follow-up diagnostic angiography was performed after 12 months using a standardized protocol and analyzed by an independent core laboratory (Genae Associates, Antwerp, Belgium). The intervals for the follow-up visits were restricted by Ϯ7 days for the 1-month follow-up and by Ϯ30 days for the 6-and 12-month visits.…”

Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral artery disease

“…To determine a >70% arteriographic restenosis in femoropopliteal arterial segments, a PSV >223 cm/s had a sensitivity of 94% and specificity of 95%, whereas a PSV ratio >2.5 identified 92% (69 of 75) of lesions. 77 Others have documented different criteria for >70% diameter reduction arteriographic restenosis, namely PSV >300 cm/s and PSV ratio >3.0, which is generally accepted and recommended. 70 Within the context of a clinical trial, we recommend that DUS imaging should be considered the standard for LE-EV intervention surveillance in an accredited noninvasive vascular laboratory at a well-defined interval.…”

Outcomes for Clinical Studies Assessing Drug and Revascularization Therapies for Claudication and Critical Limb Ischemia in Peripheral Artery Disease

“…Different validation studies report a wide range of duplex ultrasound velocity ratios (1.5-2.5), corresponding to an angiographic lumen stenosis of >50%. 53,55,[78][79][80] These are derived from studies of native disease, 55,79 post--balloon angioplasty disease, 80 and poststent disease 53,78 and often from symptomatic subgroups. Different ratios are used in different trials, but the relevance of these criteria to the recurrence of symptoms or risk of thrombosis is less clear.…”